60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals, Inc. grew revenue 73.2% to $1.11M over the twelve months to Jun 30, 2026. Free cash flow was -$8.89M. At the latest close the market valued the company at $3.31M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.31M
- P/E ratio
- –
- Price to sales
- 2.98
- Price to book
- 1.26
- Dividend yield
- –
- Free cash flow yield
- -269.05%
Fundamentals
- Revenue
- $1.11M
- Net income
- -$8.11M
- EPS, diluted
- -$11.73
- Free cash flow
- -$8.89M
- Book value per share
- $0.99
- Diluted shares
- 3M
Trading
- Previous close
- $0.03
- Open
- $0.04
- Day's range
- $0.03 – $0.04
- Volume
- 12,414
- Average volume (20 days)
- 5,599
- Beta (5 years)
- 2.04
- 52-week range
- $0.59 – $8.62
- RSI (14 days)
- 48.7
- Volatility (1 year)
- 198.9%
- Relative volume
- 0.23×
- WACC
- 15.2%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | SXTPW | S&P 500 | Difference | SXTPW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.8% | -0.9% | +3.7 pts | ||
| 3 months | -15.4% | +2.1% | −17.5 pts | ||
| Year to date | -58.8% | +11.7% | −70.4 pts | ||
| 1 year | -55.3% | +12.4% | −67.7 pts | ||
| 3 years | -76.5% | +88.6% | −165.0 pts | -38.3% | +23.5% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases 60 Degrees Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- News
About 60 Degrees Pharmaceuticals
Pharmaceutical Preparations
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes therapies to prevent and treat infectious conditions. Its primary commercial product is Arakoda, an approved tafenoquine regimen used for malaria prevention. The company also maintains development programs targeting fungal, viral, and vector-borne diseases. Its clinical pipeline explores additional regimens containing tafenoquine, alongside compounds such as celgosivir and botanical extracts derived from Australian chestnut trees. It provides treatments for individuals exposed to infectious illnesses and distributes therapies through commercial pharmaceutical distributors.
Company profile, executives and history60 Degrees Pharmaceuticals stock: common questions
What is 60 Degrees Pharmaceuticals's stock price?
SXTPW closed at $0.03 on Oct 30, 2026, down 0.38% on the day. Over the past 52 weeks it traded between $0.59 and $8.62.
What is 60 Degrees Pharmaceuticals's market cap?
60 Degrees Pharmaceuticals was worth $3.31M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is SXTPW's P/E ratio?
60 Degrees Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$11.73), so it has no meaningful P/E ratio.
How much revenue does 60 Degrees Pharmaceuticals make?
60 Degrees Pharmaceuticals reported revenue of $1.11M for the twelve months to Jun 30, 2026, up 73.2% from a year earlier.
Does 60 Degrees Pharmaceuticals pay a dividend?
No. 60 Degrees Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has SXTPW stock performed over the past year?
Including dividends, SXTPW returned -55.3% over the past year, against +12.4% for the S&P 500.
Who are 60 Degrees Pharmaceuticals's competitors?
Companies most similar to 60 Degrees Pharmaceuticals by business, industry and size include DARE, TRAW, GOVX, RFL, MNOV.